Advances
The CVC’s novel immunological monitoring strategies now allow the precise assessment and quantification of CD8+ T cell, CD4+ T cell, and antibody responses to the vaccines being investigated. The ability to induce and monitor immunization has allowed the CVC to continue the rational refinement and optimization of cancer vaccines, and vital data on variables such as constitution and delivery have been obtained. The CVC has used these monitoring strategies to show that patients receiving CVC vaccines have been successfully immunized against cancer antigens.
In fact, the CVC was the first to show a fully integrated immunological response to a cancer vaccine containing a recombinant protein target.
The CVC’s successes in identifying targets and refining vaccines have been recognized by both academia and industry, leading to codevelopment and licensing agreements with companies such as GlaxoSmithKline, CSL Ltd, and Therion.